SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells.

ABSTRACT:

Background

Basal-like breast cancer (BLBC) is a poor prognosis subgroup of triple-negative carcinomas that still lack specific target therapies and accurate biomarkers for treatment selection. P-cadherin is frequently overexpressed in these tumors, promoting cell invasion, stem cell activity and tumorigenesis by the activation of Src-Family kinase (SRC) signaling. Therefore, our aim was to evaluate if the treatment of BLBC cells with dasatinib, the FDA approved SRC inhibitor, would impact on P-cadherin induced tumor aggressive behavior.

Methods

P-cadherin and SRC expression was evaluated in a series of invasive Breast Cancer and contingency tables and chi-square tests were performed. Cell-cell adhesion measurements were performed by Atomic Force Microscopy, where frequency h

SUBMITTER: Ribeiro AS 

PROVIDER: S-EPMC6223051 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature